首页 抗体 抗体试剂盒 小包装抗体组合
Phospho-p38 MAPK Pathway Antibody Sampler Kit
Phospho-p38 MAPK Pathway Antibody Sampler Kit
1/25

Phospho-p38 MAPK Pathway Antibody Sampler Kit

分享
品牌： CST
pdf 下载产品说明书
用小程序，查商品更便捷
收藏
对比对比
咨询咨询
    产品介绍
    产品信息
    抗原名称
    p38 MAPK Pathway
    来源纯化
    Monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Thr581 of human MSK1, Thr180/Tyr182 of human p38 MAPK, Ser189 of human MKK3, Thr71 of human ATF-2, Ser82 of human HSP27 or Thr334 of human MAPKAPK-2.
    简单描述
    Antibody Sampler Kit for studying in the research area.
    应用
    目标/特异性

    Specificity/Sensitivity

    Each antibody in the Phospho-p38 MAPK Pathway Antibody Sampler Kit recognizes only the phosphorylated form of its specific target.

    背景
    背景
    p38 MAP kinase (MAPK), also called RK (1) or CSBP (2), is the mammalian orthologue of the yeast HOG kinase that participates in a signaling cascade controlling cellular responses to cytokines and stress (1-4). Four isoforms of p38 MAPK, p38α, β, γ (also known as Erk6 or SAPK3), and δ (also known as SAPK4) have been identified. Similar to the SAPK/JNK pathway, p38 MAPK is activated by a variety of cellular stresses, including osmotic shock, inflammatory cytokines, lipopolysaccharide (LPS), UV light, and growth factors (1-5). MKK3, MKK6, and SEK activate p38 MAPK by phosphorylation at Thr180 and Tyr182. Activated p38 MAPK has been shown to phosphorylate and activate MAPKAP kinase 2 (3) and to phosphorylate the transcription factors ATF-2 (5), Max (6), and MEF2 (5-8). SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole) is a selective inhibitor of p38 MAPK. This compound inhibits the activation of MAPKAPK-2 by p38 MAPK and subsequent phosphorylation of HSP27 (9). SB203580 inhibits p38 MAPK catalytic activity by binding to the ATP-binding pocket, but does not inhibit phosphorylation of p38 MAPK by upstream kinases (10).Four residues (Thr25, Thr222, Ser272 and Thr334) of MAPKAPK-2 are phosphorylated by p38 in an in vitro kinase assay (3). Phosphorylation at Thr222, Ser272 and Thr334 seems to be essential for the activity of MAPKAPK-2 (3). Activated MAPKAPK-2 can in return phosphorylate HSP27 at serines 15, 78 and 82 (3,9). Phosphorylation of HSP27 causes a change in the tertiary structure of HSP27, which shifts from large homotypic multimers to dimmers and monomers (10). It has been illustrated that phosphorylation and increased concentration of HSP27 modulate actin polymerization and reorganization (11,12). 1.Rouse, J. et al. (1994) Cell 78, 1027-37. 2.Han, J. et al. (1994) Science 265, 808-11. 3.Lee, J.C. et al. (1994) Nature 372, 739-46. 4.Freshney, N.W. et al. (1994) Cell 78, 1039-49. 5.Raingeaud, J. et al. (1995) J Biol Chem 270, 7420-6. 6.Zervos, A.S. et al. (1995) Proc Natl Acad Sci U S A 92, 10531-4. 7.Zhao, M. et al. (1999) Mol Cell Biol 19, 21-30. 8.Yang, S.H. et al. (1999) Mol Cell Biol 19, 4028-38. 9.Cuenda, A. et al. (1995) FEBS Lett 364, 229-33. 10.Kumar, S. et al. (1999) Biochem Biophys Res Commun 263, 825-31. 11.Landry, J. et al. (1992) J Biol Chem 267, 794-803. 12.Rogalla, T. et al. (1999) J Biol Chem 274, 18947-56. 13.Lavoie, J.N. et al. (1993) J Biol Chem 268, 24210-4. 14.Rousseau, S. et al. (1997) Oncogene 15, 2169-77.

    参考图片

    Flow cytometric analysis of HeLa cells, untreated (blue) or UV-treated (green), using Phospho-MAPKAPK-2 (Thr334) (27B7) Rabbit mAb.

    Western blot analysis of extracts from 293 cells, transfected with wt MSK1 or mutant MSK1, untreated or TPA-treated (200 nM), using Phospho-MSK1 (Thr581) Antibody.

    Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing nuclear localization, using Phospho-MSK1 (Thr581) Antibody.

    Western blot analysis of extracts from 293 cells, untreated, UV-treated or calyculin A-treated, using Phospho-MSK1 (Thr581) Antibody.

    After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO* is added and emits light during enzyme catalyzed decomposition.

    Western blot analysis of extracts from untreated or UV+TPA-treated HeLa and COS cells, using Phospho-MAPKAPK-2 (Thr334) (27B7) Rabbit mAb (upper), or MAPKAPK-2 Antibody #3042 (lower).

    Western blot analysis of extracts from untreated or UV-treated COS cells, NIH/3T3 cells and C6 cells, using Phospho-ATF-2 (Thr71) (11G2) Rabbit mAb (upper), or ATF-2 (20F1) Rabbit mAb #9226 (lower).

    Flow cytometric analysis of THP-1 cells, untreated (blue) or Anisomycin treated (green), using Phospho-ATF-2 (Thr71) (11G2) Rabbit mAb compared to a nonspecific negative control antibody (red).

    Western blot analysis of extracts from 293 cells untreated or treated with UV and HeLa cells untreated or treated with calyculin A, using Phospho-MSK1 (Thr581) Antibody.

    Confocal immunofluorescent analysis of HeLa cells, untreated (left), UV-treated (center) or UV and lambda phosphatase-treated (right), using Phospho-MAPKAPK-2 (Thr334) (27B7) Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red).

    Confocal immunofluorescent analysis of COS cells, untreated (left) or anisomycin-treated (right) using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red).

    Western blot analysis of extracts from 293 cells untreated or treated with UV and HeLa cells untreated or treated with calyculin A, using Phospho-MSK1 (Thr581) Antibody #9595.

    Flow cytometric analysis of Jurkat cells, untreated (blue) or anisomycin-treated (green), using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb compared to a nonspecific negative control antibody (red).

    Western blot analysis of extracts from untreated or UV-treated COS, NIH/3T3 and C6 cells, using Phospho-MKK3/6 (Ser189/207) (22A8) Rabbit mAb #9236.

    Western blot analysis of extracts from untreated or UV-treated COS cells, NIH/3T3 cells and C6 cells, using Phospho-ATF-2 (Thr71) (11G2) Rabbit mAb #5112 (upper), or ATF-2 (20F1) Rabbit mAb #9226 (lower).

    Western blot analysis of extracts from untreated or UV+TPA-treated HeLa and COS cells, using Phospho-MAPKAPK-2 (Thr334) (27B7) Rabbit mAb #3007 (upper), or MAPKAPK-2 Antibody #3042 (lower).

    Immunohistochemical analysis of paraffin-embedded 293T cell pellets, untreated (left) or UV-treated (right), using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb.

    Immunohistochemical analysis of paraffin-embedded human colon carcinoma using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb.

    Western blot analysis of extracts from COS and 293 cells, untreated or UV-treated, using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb (upper) or p38 MAPK Antibody #9212 (lower).

    Western blot analysis of extracts from COS and 293 cells, untreated or UV-treated, using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) Rabbit mAb #4511 (upper) or p38 MAPK Antibody #9212 (lower).

    Immunohistochemical analysis of paraffin-embedded HeLa cell pellets, control (left) or UV-treated (right), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb.

    Immunohistochemical analysis of paraffin-embedded human prostate carcinoma using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb.

    Immunohistochemical analysis of paraffin-embedded human breast carcinoma, control (left) or λ phosphatase-treated (right), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb.

    Immunohistochemical analysis of paraffin-embedded human lung carcinoma using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb in the presence of control peptide (left) or antigen-specific peptide (right).

    Confocal immunofluorescent analysis of C2C12 cells, untreated (left) or treated with λ phosphatase (middle), and NIH/3T3 cells (right) using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb (green). Actin filaments were labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye). Negative staining in NIH/3T3 cells is in agreement with the observation that NIH/3T3 cells do not express HSP27 under basal conditions (5,7).

    Flow cytometric analysis of HeLa cells, untreated (blue) or UV-treated (green), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb.

    Western blot analysis of extracts from HeLa or HT-29 cells, untreated (-) or treated (+) with either UV (40 mJ/cm2 with 30 min recovery) or anisomycin (25 μg/mL, 30 min), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb.

    Immunohistochemical analysis of paraffin-embedded mouse lung using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb.

    Western blot analysis of extracts from HeLa or HT-29 cells, untreated (-) or treated (+) with either UV (40 mJ/cm2 with 30 min recovery) or anisomycin (25 μg/mL, 30 min), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb #9709.

    Confocal immunofluorescent analysis of HeLa cells, untreated (left) or UV-treated (40 mJ/cm2 with 30 min recovery; right), using Phospho-MKK3 (Ser189)/MKK6 (Ser207) (D8E9) Rabbit mAb (green). Actin filaments were labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

    Western blot analysis of extracts from HeLa and NIH/3T3 cells, untreated (-) or treated with TPA #4174 (200 nM, 15 min; +), using Phospho-MKK3 (Ser189)/MKK6 (Ser207) (D8E9) Rabbit mAb (upper), MKK3 (D4C3) Rabbit mAb #8535 (middle), or MKK6 (D31D1) Rabbit mAb #8550 (lower).

    Immunoprecipitation of phospho-MKK3 (Ser189)/MKK6 (Ser207) from HeLa cells, untreated or treated with TPA #4174 (200 nM, 15 min), using Phospho-MKK3 (Ser189)/MKK6 (Ser207) (D8E9) Rabbit mAb (lanes 3 and 4) or Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (lanes 5 and 6). Lanes 1 and 2 are 10% input. Western blot analysis was performed using

    Phospho-MKK3 (Ser189)/MKK6 (Ser207) Antibody #9231. Mouse Anti-rabbit IgG (Conformation Specific) (L27A9) mAb #3678 was used as a secondary antibody.

    声明 ：本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。
    货号：
    9913T
    一键复制
    询价
    供应商现货
    1Kit
    选择数量
    当前规格1件起购 
    配送至
    预计5-6个工作日送达，快递: 免运费，若需干冰额外收费
    询价 大包装询价